Immunotherapy-related toxicity in lung cancer: clinical characteristics and managing strategy

作     者：Wen-Xin Luo Lan Yang Wei-Min Li Luo Wen-Xin;Yang Lan;Li Wei-Min

作者机构：Department of Pulmonary and Critical Care MedicineWest China HospitalSichuan UniversityChengduSichuan 610041China. 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2021年第134卷第7期

页      面：780-782页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：National Natural Science Foundation of China to Wei-Min Li(No.81871890)。 

主　　题：lung clinical cancer 

摘      要：Worldwide,lung cancer is the most common malignancy and the leading cause of cancer-related death.After the era of chemotherapy,radiotherapy,and molecular-targeted therapy,the treatment of advanced lung cancer has entered a new era of immunotherapy,represented by immune checkpoint inhibitors(ICIs),including programmed cell death protein-1/programmed cell death protein ligand-1(PD-1/PD-L1)inhibitors and cytotoxic T-lymphocyte-associated antigen-4(CTLA-4)inhibitors.[1]However,patients treated with ICIs may experience unexpected systemic toxicities,some fatal.Thus,managing immunotherapy-related toxicity has become increasingly significant in patients with lung cancer.Here,we review the latest developments on the clinical features and management of immunotherapy-related toxicity in patients with lung cancer in order to promote the standardization of immunotherapy for lung cancer.